20 May 2025
Research out this week finds that a combination of two drugs could improve outcomes and reduce the need for toxic chemotherapy for B-cell acute lymphoblastic leukaemia (B-ALL), the most common cancer in childhood and one that can be particularly difficult to treat in older patients. In recent years, new treatments have...
SCI-TIF community gathers for 3rd Annual Networking Dinner
29 April 2025
Last week, the Cambridge Stem Cell Institute Technology & Innovation Forum (SCI-TIF) celebrated its 3rd Annual Networking Dinner at Homerton College, Cambridge. This event brought together leading scientists from academia and industry, reinforcing SCI-TIF’s mission to unite the Cambridge stem cell community and foster...
Professor Sarah Teichmann announced as new member of the American Academy of Arts & Sciences
24 April 2025
Professor Sarah Teichmann FMedSci FRS, Chair in Stem Cell Medicine at the University of Cambridge (Cambridge Stem Cell Institute & Dept Medicine), and Group Leader at CSCI, has been announced this week as one of the newest members of the prestigious American Academy of Arts & Sciences . Sarah says, “ It is a...
Groundbreaking discovery from Tzelepis Lab could revolutionise treatment for deadly blood cancers
23 April 2025
A new study from Dr Konstantinos Tzelepis at the Cambridge Stem Cell Institute has discovered a new way to detect and target Acute Myeloid Leukaemia (AML), a fast growing, aggressive, blood cancer that requires urgent treatment. The research was published today (23 April) in Nature Biotechnology. AML is the second most...